Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
<< vorige    volgende >>
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
           Alle artikelen van de bijbehorende aflevering
                                       Details van artikel 129 van 132 gevonden artikelen
 
 
  The pharmacokinetics of ^{131}I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab
 
 
Titel: The pharmacokinetics of ^{131}I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab
Auteur: Tran, L.
Baars, J.W.
de Boer, J.P.
Hoefnagel, C.A.
Beijnen, J.H.
Huitema, A.D.R.
Verschenen in: Human antibodies
Paginering: Jaargang 20 (2011) nr. 1-2 pagina's 37-40
Jaar: 2011-05-10
Inhoud: Purpose: To report the pharmacokinetics of ^{131}I-rituximab a patient with a CD20 positive non-Hodgkin Lymphoma who has received ^{131}I-rituximab as consolidation treatment after remission induction and to evaluate the effect of radioiodination on the biological properties of rituximab. Results: The patient was a 65-year-old male with a relapsed CD20 positive follicular non-Hodgkin Lymphoma. After induction therapy the patient was in partial remission. Following administration of a diagnostic dose of 185 MBq ^{131}I-rituximab, remaining lesions were identified on the wholebody scans. The patient then received a therapeutic dose of 1000 MBq ^{131}I-rituximab. The uptake by the tumor in the right axilla was 0.17–0.21% of the injected dose. The calculated biological half-life of ^{131}I-rituximab was 684 hrs. This biological half-life corresponded well with the half-life of unlabeled rituximab which was approximately 720 hrs. Discussion and conclusion: Even though radioiodination of rituximab results in a reduced binding capacity, whole body scans demonstrated localization of ^{131}I-rituximab in the tumor area. This observation supports the specific targeting of ^{131}I-rituximab. The half-life of ^{131}I-rituximab corresponded to the half-life of unlabeled rituximab. Hence, the pharmacokinetics of ^{131}I-rituximab was not relevantly affected by the radioiodination process.
Uitgever: IOS Press
Bronbestand: Elektronische Wetenschappelijke Tijdschriften
 
 

                             Details van artikel 129 van 132 gevonden artikelen
 
<< vorige    volgende >>
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland